ESMO Open : Impact Factor & More

LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional study

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review.

Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer.

Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer.

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional study

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review.

Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer.

Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer.

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.